ArticleArchives of women's mental health2022
Allopregnanolone and depression and anxiety symptoms across the peripartum: an exploratory study.
Article in Archives of women's mental health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 18 citations in OpenAlex.
- Neurobiological insights into perinatal depression: a multi-dimensional integration of brain structure, function, and metabolism.Frontiers in psychiatry · 2026Pooled it
- Peripartum allopregnanolone blood concentrations and depressive symptoms: a systematic review and individual participant data meta-analysis.Molecular psychiatry · 2025Pooled it
- The immune phenotype of perinatal anxiety in an anxiety-focused behavioral intervention program in Pakistan.Brain, behavior, and immunity · 2024Trial
- The impact of mental health disorders in pregnancy on obstetric and neonatal outcomes: A narrative review.Brain, behavior, & immunity - health · 2026Review
- 5α-Reductase Isoenzymes: From Neurosteroid Biosynthesis to Neuropsychiatric Outcomes.NeuroSci · 2026Review
- Biomarkers of reproductive psychiatric disorders.The British journal of psychiatry : the journal of mental science · 2025Review
- Neuroactive steroid biosynthesis during pregnancy predicts future postpartum depression: a role for the 3α and/or 3β-HSD neurosteroidogenic enzymes?Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2025Article
- AMP-Activated Protein Kinase Treatment Ameliorates Chronic Restraint Stress Induced Memory Impairment in Early Adolescent Rat by Restoring Metabolite Profile and Synaptic Proteins.Neurochemical research · 2024Article
- Functional Food Nutrients, Redox Resilience Signaling and Neurosteroids for Brain Health.International journal of molecular sciences · 2024Review
- Allopregnanolone and mood in the peripartum: a longitudinal assessment in healthy women.Frontiers in behavioral neuroscience · 2024Article
- The link between childhood traumatic events and the continuum of premenstrual disorders.Frontiers in psychiatry · 2024Article
- Metabolites of progesterone in pregnancy: Associations with perinatal anxiety.Psychoneuroendocrinology · 2023Article
- Biological Mechanisms in Pregnant Women With Anxiety (Happy Mother-Healthy Baby Supplement Study): Protocol for a Longitudinal Mixed Methods Observational Study.JMIR research protocols · 2023Article
- The importance of translationally evaluating steroid hormone contributions to substance use.Frontiers in neuroendocrinology · 2023Review
- Zuranolone - synthetic neurosteroid in treatment of mental disorders: narrative review.Frontiers in psychiatry · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
Recent research has implicated allopregnanolone (ALLO), a neuroactive steroid and metabolite of progesterone, in perinatal mood and anxiety symptoms. We sought to add to the limited literature examining ALLO and mood and anxiety at multiple time points across the peripartum. We measured mood and anxiety symptoms and ALLO levels by ELISA at the second and third trimester (T2 and T3) and week 6 postpartum (W6) in N = 73 women with prior histories of mood and/or anxiety disorders and N = 38 healthy controls. Analytic methods included multivariate and logistic regressions with linear mixed effect models. Among all participants (N = 111), higher ALLO levels at W6 were associated with higher depression and anxiety scores: each one unit increase in log ALLO at W6 was associated with a 2.54 point increase on the Edinburgh Postnatal Depression Scale (EPDS) (95% CI: 0.73 to 4.33) and an 8.0 point increase on the Perinatal Anxiety Screening Scale (PASS) (95% CI: 3.82 to 12.6). In addition, the nature of the relationship between log ALLO level and psychological measures changed across time; from T2 to W6 for EPDS, β = 3.73 (95% CI:1.16, 6.30), p = 0.0045; for PASS β = 9.78 (95% CI:3.77, 15.79), p = 0.0014); from T3 to W6, for (EPDS, β = 2.52 (95% CI:0.08, 4.96), p = 0.043; for PASS β = 7.33 (95% CI:1.63, 13.02), p = 0.018). The relationship of log ALLO to mood and anxiety symptoms was the same among women with and without psychiatric histories. Our exploratory findings indicate that the relationship between ALLO and mood and anxiety symptoms may change across the peripartum.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.